Flavopiridol hydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种有效的 ATP 竞争性 CDK 抑制剂，对 CDk1、2、4 的 IC50 分别为 30、170、100 nM。

A potent, ATP-competetive CDKs inhibitor with IC50 of 30, 170, 100 nM for CDk1, 2, 4, respectively; inhibits cell cycle progression in either G1 or G2 in human breast carcinoma cells, induces programmed cell death, promote differentiation, inhibits angiogenic processes and modulates transcriptional events.Blood Cancer Phase 2 Clinical(In Vitro):Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol.

Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol.

——

HL 275 | NSC 649890 | MDL 107826A | | Alvocidib Hydrochloride

Cell Cycle/DNA Damage

CDK

CDK1|CDK2|CDK4|CDK6|CDK7

Cancer

Blood cancer

131740-09-5

438.3011

C21H21Cl2NO5

>98% (HPLC)

10 mM in DMSO

CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl

4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-, hydrochloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years